Abstract
The spinal reflex depressant mechanism of tolperisone and some of its structural analogs with central muscle relaxant action was investigated. Tolperisone (50–400 μM), eperisone, lanperisone, inaperisone, and silperisone (25–200 μM) dose dependently depressed the ventral root potential of isolated hemisected spinal cord of 6-day-old rats. The local anesthetic lidocaine (100–800 μM) produced qualitatively similar depression of spinal functions in the hemicord preparation, whereas its blocking effect on afferent nerve conduction was clearly stronger. In vivo, tolperisone and silperisone as well as lidocaine (10 mg/kg intravenously) depressed ventral root reflexes and excitability of motoneurons. However, in contrast with lidocaine, the muscle relaxant drugs seemed to have a more pronounced action on the synaptic responses than on the excitability of motoneurons. Whole-cell measurements in dorsal root ganglion cells revealed that tolperisone and silperisone depressed voltage-gated sodium channel conductance at concentrations that inhibited spinal reflexes. Results obtained with tolperisone and its analogs in the [3H]batrachotoxinin A 20-α-benzoate binding in cortical neurons and in a fluorimetric membrane potential assay in cerebellar neurons further supported the view that blockade of sodium channels may be a major component of the action of tolperisone-type centrally acting muscle relaxant drugs. Furthermore, tolperisone, eperisone, and especially silperisone had a marked effect on voltagegated calcium channels, whereas calcium currents were hardly influenced by lidocaine. These data suggest that tolperisone-type muscle relaxants exert their spinal reflex inhibitory action predominantly via a presynaptic inhibition of the transmitter release from the primary afferent endings via a combined action on voltage-gated sodium and calcium channels.
Footnotes
-
doi:10.1124/jpet.105.089805.
-
ABBREVIATIONS: TTX, tetrodotoxin; DRG, dorsal root ganglion; NMDA, N-methyl-d-aspartate; [3H]BTX, [3H]batrachotoxinin A 20-α-benzoate; ACSF, artificial cerebrospinal fluid; DR-VRP, dorsal root stimulation-evoked ventral root potential; AFP, afferent fiber potential; MN, motoneuron stimulation-related compound action potential; MS, monosynaptically evoked action potential of motoneurons; PAF, primary afferent fiber; ES, extracellular solution; IS, intracellular solution; MSR, monosynaptic reflex; EPSP, excitatory postsynaptic potential; DSR, disynaptic reflex; PSR, polysynaptic reflex; GYKI 52466, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride.
- Received May 26, 2005.
- Accepted August 25, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|